A217730 logo

Kangstem Biotech Co., Ltd. Stock Price

KOSDAQ:A217730 Community·₩201.7b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

A217730 Share Price Performance

₩0
-1950.00 (-100.00%)
₩0
-1950.00 (-100.00%)
Price ₩0

A217730 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Adequate balance sheet with very low risk.

2 Risks
1 Reward

Kangstem Biotech Co., Ltd. Key Details

₩12.8b

Revenue

₩11.0b

Cost of Revenue

₩1.8b

Gross Profit

₩11.9b

Other Expenses

-₩10.1b

Earnings

Last Reported Earnings
Sep 30, 2024
Next Reporting Earnings
n/a
-107.27
13.91%
-78.98%
14.6%
View Full Analysis

About A217730

Founded
2010
Employees
97
CEO
Jong-Cheon Na
WebsiteView website
www.kangstem.com

Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn’s disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and platelet-derived growth factors, as well as growth and differentiation factor 11, and Fibroblast growth factor 2 for skin growth and regeneration. In addition, the company offers stem cell culture media, including KSB-3 kit, a medium for culturing the human mesenchymal stem cell; and cell freezing and thawing platform. Further, it provides pharmaceutical contract manufacturing and development services. Kangstem Biotech Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.

Recent A217730 News & Updates

Recent updates

No updates